ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 4 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,108,341 | -21.5% | 115,241 | +2.7% | 1.22% | +10.7% |
| Q2 2023 | $5,236,042 | +17.9% | 112,241 | +1.4% | 1.10% | -26.0% |
| Q1 2023 | $4,440,714 | -7.9% | 110,741 | +3.7% | 1.49% | -18.4% |
| Q4 2022 | $4,821,491 | +44.4% | 106,741 | +29.6% | 1.83% | +50.7% |
| Q3 2022 | $3,339,000 | -46.6% | 82,341 | -21.5% | 1.21% | -41.5% |
| Q2 2022 | $6,258,000 | -23.6% | 104,899 | -6.9% | 2.07% | +14.6% |
| Q1 2022 | $8,186,000 | -4.6% | 112,727 | +10.7% | 1.81% | +6.4% |
| Q4 2021 | $8,579,000 | – | 101,831 | – | 1.70% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |